drugset / Trial / NCT00529009

Pharmacokinetic Investigation of UDCA in Bile and Serum

NCT00529009

Phase 1 Completed Dr. Falk Pharma GmbH
Non-randomizedParallel-groupOpen-label

Summary

To assess the bile acid composition of cystic bile and serum pharmaco¬kinetics after a 3-week treatment with UDCA and to correlate pharmacokinetic parameters of UDCA in bile and serum during steady state.

Timeline

Start
2007-05
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ursodeoxycholic Acid Small molecule 15 mg/kg

Indications

No indication recorded.